Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Forte Biosciences, Inc.NASDAQ: FBRX
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q1 FY2026 gross profit was -$19K, compared with -$13K a year earlier. Trailing-twelve-month gross profit was -$6K.
Context
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$19K or moves back toward the trailing-twelve-month quarterly average of -$1.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (64K) USD
- Year-over-year change
- -64.1%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (64K) | -64.1% |
| FY2024 | 2024-12-31 | (39K) | -333.3% |
| FY2023 | 2023-12-31 | (9K) | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (36K) | — |
Gross Profit vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +86.0% is the 3rd highest of 8, against a peer median of +63.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | -$6K USD | +86.0% | — | — | |
| LTM Mar 2026 | -$149K USD | +99.1% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$289K USD | +75.2% | — | — |
| LTM Mar 2026 | -$1.72M USD | -351.6% | — | — | |
| LTM Mar 2026 | -$2.34M USD | — | — | — | |
| LTM Mar 2026 | -CHF 2.61M CHF | +91.8% | — | — | |
| LTM Mar 2026 | -$11.06M USD | -20.7% | +15.4% | 2105.7% | |
| LTM Mar 2026 | -$11.28M USD | -289.4% | -56.0% | 61.2% | |
| LTM Mar 2026 | -$26.26M USD | +63.7% | — | 415.8% | |
| Peer median (excluding FBRX) | — | +63.7% | -20.3% | 415.8% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.